Patent 7605239 was granted and assigned to Poniard Pharmaceuticals, Inc. on October, 2009 by the United States Patent and Trademark Office.
The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.